Executive Director and CEO Dr. Yang Jianxin Raises Stake in CStone Pharmaceuticals with Share Purchase

Stock News

Sep 17

New data from the Hong Kong Stock Exchange reveals that on September 17, Executive Director and Chief Executive Officer Dr. Yang Jianxin increased his shareholding in CStone Pharmaceuticals-B (HKEX: 2616) by 132,500 shares.

The shares were acquired at an average price of HK$5.2361 per share, with a total transaction value of approximately HK$693,800. Following the increase, Dr. Yang's latest shareholding stands at roughly 84.42 million shares, bringing his total stake in the company to 5.29%.

The purchase was made in the open market using Dr. Yang's personal funds. These additional shares represent Restricted Share Units and Share Options that have been granted or are pending issuance to Dr. Yang under the company's Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1125656820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125656820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125656820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125656820","market":"us","top_or_hot":-1,"title":"Executive Director and CEO Dr. Yang Jianxin Raises Stake in CStone Pharmaceuticals with Share Purchase","media":"Stock News","content":"<p>New data from the Hong Kong Stock Exchange reveals that on September 17, Executive Director and Chief Executive Officer Dr. Yang Jianxin increased his shareholding in <b>CStone Pharmaceuticals-B (HKEX: 2616)</b> by 132,500 shares.<br><br>The shares were acquired at an average price of HK$5.2361 per share, with a total transaction value of approximately HK$693,800. Following the increase, Dr. Yang's latest shareholding stands at roughly 84.42 million shares, bringing his total stake in the company to 5.29%.<br><br>The purchase was made in the open market using Dr. Yang's personal funds. These additional shares represent Restricted Share Units and Share Options that have been granted or are pending issuance to Dr. Yang under the company's Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Executive Director and CEO Dr. Yang Jianxin Raises Stake in CStone Pharmaceuticals with Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExecutive Director and CEO Dr. Yang Jianxin Raises Stake in CStone Pharmaceuticals with Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-17 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>New data from the Hong Kong Stock Exchange reveals that on September 17, Executive Director and Chief Executive Officer Dr. Yang Jianxin increased his shareholding in <b>CStone Pharmaceuticals-B (HKEX: 2616)</b> by 132,500 shares.<br><br>The shares were acquired at an average price of HK$5.2361 per share, with a total transaction value of approximately HK$693,800. Following the increase, Dr. Yang's latest shareholding stands at roughly 84.42 million shares, bringing his total stake in the company to 5.29%.<br><br>The purchase was made in the open market using Dr. Yang's personal funds. These additional shares represent Restricted Share Units and Share Options that have been granted or are pending issuance to Dr. Yang under the company's Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1125656820","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125656820","pubTimestamp":1789645575,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"New data from the Hong Kong Stock Exchange reveals that on September 17, Executive Director and Chief Executive Officer Dr. Yang Jianxin increased his shareholding in CStone Pharmaceuticals-B (HKEX:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","BK1574":"生物医药B类股","EWH":"香港ETF-iShares MSCI","BK1161":"生物科技"},"translate_title":"执行董事兼行政总裁杨建新博士通过购买股份增持基石药业股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"EWH":1},"content_text":"New data from the Hong Kong Stock Exchange reveals that on September 17, Executive Director and Chief Executive Officer Dr. Yang Jianxin increased his shareholding in CStone Pharmaceuticals-B (HKEX: 2616) by 132,500 shares.The shares were acquired at an average price of HK$5.2361 per share, with a total transaction value of approximately HK$693,800. Following the increase, Dr. Yang's latest shareholding stands at roughly 84.42 million shares, bringing his total stake in the company to 5.29%.The purchase was made in the open market using Dr. Yang's personal funds. These additional shares represent Restricted Share Units and Share Options that have been granted or are pending issuance to Dr. Yang under the company's Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}